Further data of mesdopetam's Ph 2b trial in H1'23e
No material events occurred during Q4. In January, IRLAB announced the top-line data from its Ph 2b trial of mesdopetam in Parkinson's disease levodopa induced dyskinesia (PD-LIDs), where the primary endpoint was not met (change in average daily hours of ON-time without troublesome dyskinesia assessed by patient diaries). However, the company pointed out positive anti-dyskinetic results based on the secondary endpoint UDysRS. IRLAB recently received the full data and is now performing an in-depth analysis of all the generated data with Ipsen. Based on the results of the analysis, Ipsen will decide if it considers the asset promising enough to move it into Ph 3 or not, we believe. The results are expected to be presented in a scientific congress in H1'23e. IRLAB also announced the nomination of IRL1117 as drug candidate from the P003 project, intended to be developed as a new treatment for PD. IRL1117 continues with in-house activities in preparation for tox and manufacturing activities in '24. IRLAB provided last week an updated timeline for the upcoming milestones following an assessment of the operational priorities for the year. Finally, IRLAB's CEO Richard Godfrey has been replaced by Gunnar Olsson (Chairman of the Board), who was appointed new Interim CEO.
Aktuellt
SENASTE
